Miroslaw J Szczepanski
Overview
Explore the profile of Miroslaw J Szczepanski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
2372
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Czerwaty K, Piszczatowska K, Szczepanski M, Jermakow N, Ludwig N, Dzaman K
Int Forum Allergy Rhinol
. 2025 Mar;
:e23563.
PMID: 40067202
Background: The pathogenesis of inflammation in eosinophilic chronic rhinosinusitis (ECRS) and non-eosinophilic chronic rhinosinusitis (NECRS) remains poorly understood. This study aimed to assess immune cell infiltration within the sinonasal microenvironment...
2.
Westermann L, Diergaarde B, Heidegger S, Poeck H, Szczepanski M, Reichert T, et al.
Clin Transl Oncol
. 2025 Jan;
PMID: 39776398
Background: Small extracellular vesicles (sEV) released by tumor cells (tumor-derived sEV; TEX) mediate intercellular communication between tumor and non-malignant cells and were shown to impact disease progression. This study investigates...
3.
Piszczatowska K, Czerwaty K, Dzaman K, Jermakow N, Brzost J, Kantor I, et al.
J Pers Med
. 2024 Sep;
14(9).
PMID: 39338148
Chronic rhinosinusitis with and without nasal polyps (CRSwNP and CRSsNP, respectively) is a chronic inflammatory disease affecting almost 5 to 12% of the population and exhibiting high recurrence rates after...
4.
Siewiera J, Smolenski M, Jermakow N, Kot J, Reichert T, Miskiewicz P, et al.
Arch Med Sci
. 2024 May;
20(2):476-484.
PMID: 38757025
Introduction: Hyperbaric oxygen (HBO) therapy involves the inhalation of pure oxygen in a pressure chamber under increased ambient pressure. Recent research indicates that circulating small extracellular vesicles (sEVs) play important...
5.
Zareba L, Piszczatowska K, Dzaman K, Soroczynska K, Motamedi P, Szczepanski M, et al.
J Pers Med
. 2024 Jan;
14(1).
PMID: 38248800
PM2.5 is one of the most harmful components of airborne pollution and includes particles with diameters of less than 2.5 μm. Almost 90% of the world's population lives in areas...
6.
Hofmann L, Harasymczuk M, Huber D, Szczepanski M, Dworacki G, Whiteside T, et al.
Cancers (Basel)
. 2023 Nov;
15(22).
PMID: 38001706
Immunoregulatory Arginase-1 (Arg-1) is present in the tumor microenvironment of solid tumors. Its association to clinicopathology and its prognostic impact are inconsistent among different tumor types and biological fluids. This...
7.
Luczak M, Dzaman K, Zareba L, Czerwaty K, Siewiera J, Gluszko A, et al.
Diagnostics (Basel)
. 2023 Nov;
13(22).
PMID: 37998605
Cholesteatoma is a specific medical condition involving the abnormal, non-cancerous growth of skin-like tissue in the middle ear, potentially leading to a collection of debris and even infections. The receptor...
8.
Dzaman K, Czerwaty K, Reichert T, Szczepanski M, Ludwig N
Int J Mol Sci
. 2023 Aug;
24(15).
PMID: 37569652
Cholesteatoma is a temporal bone disease characterized by dysfunctions of keratinocytes. MicroRNAs (miRNAs) are evolutionary conserved noncoding RNAs that regulate mRNA expression. They can be packaged into exosomes and transported...
9.
Ludwig N, Yerneni S, Harasymczuk M, Szczepanski M, Gluszko A, Kukwa W, et al.
Br J Cancer
. 2023 Feb;
128(9):1733-1741.
PMID: 36810911
Objectives: Contributions of TGFβ to cancer progression are well documented. However, plasma TGFβ levels often do not correlate with clinicopathological data. We examine the role of TGFβ carried in exosomes...
10.
Kallinger I, Rubenich D, Gluszko A, Kulkarni A, Spanier G, Spoerl S, et al.
Clin Exp Immunol
. 2023 Feb;
213(1):102-113.
PMID: 36752300
Head and neck squamous cell carcinomas (HNSCCs) evade immune responses through multiple resistance mechanisms. Extracellular vesicles (EVs) released by the tumor and interacting with immune cells induce immune dysfunction and...